May 30, 2014Pershing Square Capital Management, L.P. • June 2nd, 2014 • Pharmaceutical preparations
Reference is made to (i) that certain letter agreement, dated as of February 9, 2014 (the “Confidentiality Agreement”), between Pershing Square Capital Management, L.P. (together with its controlled affiliates, and including any successor thereto, “you” or “Pershing Square”) and Valeant Pharmaceuticals International, Inc. (together with its controlled affiliates, and including any successor thereto, the “Company”) and (ii) that certain letter agreement, dated as of February 25, 2014 (the “February 25 Letter Agreement” between Pershing Square and the Company executed in connection with a potential transaction related to Allergan, Inc. (“Allergan”). Capitalized terms used herein but not defined herein shall have the meanings given to such terms in the February 25 Letter Agreement.
